The prevalence of tumour markers in malignant pleural effusions associated with primary pulmonary adenocarcinoma: a retrospective study.

Fjaellegaard, Katrine; Koefod Petersen, Jesper; Andersen, Gitte; Biagini, Matteo; Bhatnagar, Rahul; Laursen, Christian B; Clementsen, Paul Frost; Bodtger, Uffe

Fjaellegaard, Katrine; Koefod Petersen, Jesper; Andersen, Gitte; Biagini, Matteo; Bhatnagar, Rahul; Laursen, Christian B; Clementsen, Paul Frost; Bodtger, Uffe.

Afiliação

Fjaellegaard K; Department of Respiratory Medicine, Zealand University Hospital Naestved, Naestved, Denmark.
Koefod Petersen J; Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark.
Andersen G; Department of Respiratory Medicine, Zealand University Hospital Naestved, Naestved, Denmark.
Biagini M; Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark.
Bhatnagar R; Department of Pathology, Zealand University Hospital Roskilde, Roskilde, Denmark.
Laursen CB; Department of Pathology, Zealand University Hospital Roskilde, Roskilde, Denmark.
Clementsen PF; Department of Respiratory Medicine, Southmead Hospital, North Bristol NHS Trust, Bristol, UK.
Bodtger U; Academic Respiratory Unit, University of Bristol, Bristol, UK.

Eur Clin Respir J ; 8(1): 1984375, 2021.

Article em En | MEDLINE | ID: mdl-34745460

Palavras-chave

Lung cancer; anaplastic lymphoma kinase (ALK); epidermal growth factor receptor (EGFR) mutation; malignant pleural effusion; programmed death-ligand 1 (PD-L1); pulmonary adenocarcinoma; tumour markers

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google